Namrata Sonia Chandhok MD
Hematologic Oncology
Assistant Professor of Clinical Medicine Clinical Co-Leader, Leukemia Site Disease Group
Join to View Full Profile
1611 NW 12th AveUniversity of Miami- Malignant HematologyMiami, FL 33136
Dr. Chandhok is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Namrata Chandhok is a hematologist specializing in hematologic oncology based in Miami, FL. She completed her medical training at George Washington University and carried out her residency in internal medicine at Tufts Medical Center, followed by a fellowship in medical oncology at Yale-New Haven Medical Center. Dr. Chandhok has significant experience with bone marrow failure syndromes, and she was employed as a fellow at Yale-New Haven Hospital until 2023. Her research is well-published, with notable work on clonal cytopenia and oncogenic mutations impacting chromatin landscapes.
Education & Training
Yale-New Haven Medical CenterFellowship, Medical Oncology, 2017 - 2019
Tufts Medical CenterResidency, Internal Medicine, 2013 - 2016
George Washington University School of Medicine and Health SciencesClass of 2013
Certifications & Licensure
FL State Medical License 2019 - 2027
CT State Medical License 2016 - 2021
MA State Medical License 2013 - 2016
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 6 citationsRisk prediction for clonal cytopenia: multicenter real-world evidence.Zhuoer Xie, Rami Komrokji, Najla Al Ali, Alexandra Regelson, Susan Geyer
Blood. 2024-11-07 - 14 citationsTranscription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape.Prajwal C Boddu, Abhishek K Gupta, Rahul Roy, Bárbara De La Peña Avalos, Anne Olazabal-Herrero
Molecular Cell. 2024-04-18 - Combining lenalidomide with erythropoiesis stimulating agents: a party of one.Namrata S Chandhok, Mikkael A Sekeres
Leukemia. 2024-03-01
Abstracts/Posters
- PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH InhibitorsNamrata S Chandhok, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Mye...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Rel...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
Sylvester Junior Faculty Selected for K12 Research GrantsMay 16th, 2023- Sylvester Pursues Landmark Research Presented at International Hematology ConferenceJanuary 30th, 2023
- Castaways Against Cancer Complete Carry on TourJune 23rd, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
